Diabetes mellitus (DM) is recognized as a major contributor to impaired testicular function and compromised male fertility. In the present study, the protective effects of the natural flavonoid diosmin (Dios) against diabetes-induced testicular injury were investigated using a rat model of streptozotocin (STZ)-induced diabetes. Diabetes was induced in rats via a single intraperitoneal injection of STZ at a dose of 50 mg/kg body weight. Dios was administered at doses of 25 and 50 mg/kg body weight for eight weeks. Diabetic rats displayed marked testicular dysfunction, evidenced by reduced serum testosterone levels, deteriorated sperm parameters, and pronounced histopathological alterations in testicular tissues. Biochemical analysis revealed elevated levels of oxidative stress markers, including malondialdehyde and protein carbonyls, along with decreased levels of reduced glutathione and diminished activities of catalase and superoxide dismutase in the testicular tissues. Furthermore, diabetes exacerbated testicular inflammation, as indicated by increased immunoexpression of NF-κB p65 and levels of pro-inflammatory cytokines. Likewise, diabetes induced testicular apoptosis, demonstrated by increased Bax and caspase-3 levels and decreased Bcl-2 levels. Treatment of diabetic rats with Dios significantly attenuated sperm parameters and testicular architecture and mitigated oxidative stress, inflammatory responses, and apoptotic cell death. Additionally, Dios enhanced antioxidant defense mechanisms and restored the Sirt1/Nrf2/HO-1 signaling pathway in the testicular tissues of diabetic rats. These results suggest that Dios may serve as an adjuvant therapeutic agent for diabetes-associated testicular dysfunction.

Background/Objectives: Artemisia annua essential oil (EO) possesses diverse biological activities; however, its practical application is limited by volatility, instability, and poor bioavailability. This study aimed to develop chitosan-coated nanostructured lipid carriers (CH-NLCs) for efficient encapsulation and delivery of A. annua EO and to evaluate their physicochemical characteristics and biological performance. Methods: The nanoformulation exhibited favorable physicochemical properties, including a high encapsulation efficiency (85.97 ± 1.30%) and a strongly positive surface charge (approximately +45 mV), indicating good colloidal stability. Structural analyses by SEM, FTIR, and XRD confirmed successful encapsulation of the EO within the nanocarrier matrix. Results: The CH-NLC formulation significantly enhanced larvicidal activity against Aedes aegypti larvae, reducing the LC₅₀ value from 213 ppm for the free EO to 142 ppm. Enhanced antifungal activity was also observed, with 47–56% greater inhibition against Malassezia furfur, Trichophyton mentagrophytes, and Candida albicans compared with the free EO. Furthermore, CH-NLC demonstrated improved cytotoxic activity against skin cancer cell lines, achieving IC₅₀ values of 21.4 ± 1.7 µg/mL and 30.1 ± 1.6 µg/mL against A431 and A375 cells, respectively, while maintaining lower toxicity toward normal HaCaT keratinocytes. Mechanistic investigations revealed enhanced apoptosis and an approximately 3-fold increase in intracellular reactive oxygen species (ROS) levels in treated cancer cells. Conclusions: Collectively, these findings indicate that chitosan-coated nanostructured lipid carriers effectively improve the stability and biological efficacy of A. annua essential oil and represent a promising platform for future biomedical and biocidal applications.